Clinical Trials Browser

Phase 2 × OTHER × Adrenal Cortex Neoplasms × Clear all

NCT06006013 2026-02-18

Cabozantinib in Combination With Pembrolizumab for the Treatment of Patients With Locally Advanced, Metastatic, or Unresectable Adrenal Cortical Cancer

Phase 2 Recruiting

21 enrolled

Endocrine

Adrenal Cortex Neoplasms, Adrenocortical Carcinoma

NCT02721732 2026-01-29

Pembrolizumab in Treating Patients With Rare Tumors That Cannot Be Removed by Surgery or Are Metastatic

Phase 2 Active not recruiting

157 enrolled 26 charts

CNSEndocrineGenitourinary

Adrenal Cortex Neoplasms, Carcinoma, Renal Cell, Neoplasm Metastasis, Neoplasms, Unknown Primary, Paraganglioma, Penile Neoplasms, Pheochromocytoma, Carcinoma, Small Cell, Vascular Neoplasms

NCT03370718 2024-12-10

Cabozantinib in Treating Patients With Locally Advanced or Metastatic Unresectable Adrenocortical Carcinoma

Phase 2 Completed

18 enrolled 5 charts

Adrenal Cortex Neoplasms

NCT03612232 2024-08-19

CaboACC

Phase 2 Unknown

37 enrolled

Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms, Adrenocortical Carcinoma

NCT02720484 2019-05-01

Nivolumab in Treating Patients With Metastatic Adrenocortical Cancer

Phase 2 Terminated

10 enrolled 11 charts

Adrenal Cortex Neoplasms

NCT00215202 2018-05-17

Phase II Trial of ZD1839 (Iressa) in Patients With Nonresectable Adrenocortical Carcinoma (ACC)

Phase 2 Completed

16 enrolled

Endocrine

Adrenal Cortex Neoplasms, Adrenal Gland Neoplasms